Core Viewpoint - The company, LuKang Pharmaceutical, has announced a plan to utilize part of its idle raised funds for cash management, ensuring that it does not affect the normal operation of investment projects [2] Group 1: Company Announcement - On January 23, 2026, LuKang Pharmaceutical held the twelfth (temporary) meeting of the eleventh board of directors to approve the proposal for cash management using idle raised funds [2] - The company will use an amount not exceeding RMB 31 million for cash management, with a validity period of 12 months from the date of board approval [2] - A dedicated settlement account for cash management products has been opened at the Jining Jin Yu Road Branch of China Postal Savings Bank [2]

人民财讯1月23日电，*ST长药（300391）1月23日公告，公司于2026年1月23日收到深圳证券交易所下 发的《事先告知书》,拟决定终止公司股票上市交易。公司股票自2026年1月26日开市起停牌。 ...

证券日报网讯 1月23日，雅本化学在互动平台回答投资者提问时表示，目前公司医药业务聚焦创新医药 中间体、原料药CDMO服务，暂未涉及创新药自主研发与商业化布局。 （文章来源：证券日报） ...

Core Viewpoint - The company emphasizes its commitment to a global development strategy, with the EU region being a key area for overseas operations [1] Group 1: Business Strategy - The company has established and operates a mature regional center in Germany, enhancing local service capabilities and customer response efficiency [1] - The EU region is a significant source of overseas revenue and supports the sustainable and healthy development of the company's international business [1] Group 2: Sales Model - The company adopts a direct sales model in major global markets, including the EU, allowing it to directly serve local customers [1] - This approach enables the company to deeply understand market demands and provide efficient, professional pre-sales, sales, and post-sales services [1] - The company aims to build strong customer relationships and enhance brand influence through its direct engagement strategy [1]

Core Viewpoint - The company primarily engages in the research, production, and sales of steroid drug raw materials, with a focus on progesterone products for gynecological and family planning medications [2] Group 1: Company Operations - The company is involved in the development, production, and sales of steroid drug raw materials [2] - The company's fundraising projects and steroid raw material production projects include the extension of progesterone products for downstream applications [2] - The company's products are categorized based on sales regions, which include domestic and international sales [2]

Core Viewpoint - Beilu Pharmaceutical announced that its subsidiary, Zhejiang Haichang Pharmaceutical, received a new High-tech Enterprise Certificate, indicating its continued recognition as a high-tech entity in the industry [1]. Group 1: Company Announcement - Beilu Pharmaceutical's subsidiary, Zhejiang Haichang Pharmaceutical, has been re-certified as a high-tech enterprise by the Zhejiang Provincial Department of Economy and Information Technology, Zhejiang Provincial Department of Finance, and the State Taxation Administration of Zhejiang Province [1]. - The certificate number is GR202533008197, with an issuance date of December 19, 2025, and it is valid for three years [1]. - This re-certification follows the expiration of the previous high-tech enterprise certificate held by Haichang Pharmaceutical [1].

Group 1 - The company, Jinkai Biotechnology, announced an expected net profit attributable to shareholders for the year 2025 ranging from 92 million to 116 million yuan, representing a year-on-year growth of 138.28% to 200.45% [2]

Group 1 - The company LuKang Pharmaceutical held its 12th temporary board meeting on January 23, 2026, to discuss the proposal regarding the use of raised funds to replace previously invested self-raised funds [1] - The meeting was conducted in a hybrid format, combining in-person and communication methods [1] Group 2 - Local state-owned assets have begun purchasing foreclosed properties, acquiring over 60 units in the Nansha District of Guangzhou at prices around 6,000 to 7,000 yuan per unit, while the average listing price for second-hand homes in the same community exceeds 20,000 yuan [1]

Core Viewpoint - The company plans to utilize part of its idle raised funds for cash management, ensuring that this will not affect the progress of investment projects or normal operations [1] Group 1: Financial Management - The company will use up to 310 million yuan of temporarily idle raised funds for cash management [1] - The investment period for these funds will not exceed 12 months, allowing for rolling use within the specified limit and timeframe [1] - Investment directions include high-safety, high-liquidity principal-protected products such as agreed deposits, time deposits, and large-denomination certificates of deposit [1]

拓新药业1月23日公告，预计2025年归母净利润亏损5400万元–7300万元，上年同期亏损1988.49万元。 ...